LOS ANGELES, CA / ACCESS Newswire / February 6, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...
EST Alto Neuroscience (ANRO) files $300M mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the power of ...
Shares of Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) have earned an average rating of “Moderate Buy” from the ...
Alto Neuroscience , Inc. (NYSE:ANRO), a pharmaceutical company currently trading at $4.18 per share, has entered into a Sales Agreement with Leerink Partners LLC, initiating an "at the market" ...
MOUNTAIN VIEW, Calif., December 11, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
After hours: February 3 at 6:20:25 PM EST Loading Chart for ANRO ...
Poscierre: January 31 at 5:57:47 p.m. EST ...
Jan. 30, 2025 — Shorter protective caps on chromosomes called telomeres, a proposed marker of accelerated biological cell aging, may be associated with an increased risk of stroke, dementia and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback